QT
CHRS icon

Quantbot Technologies’s Coherus Oncology CHRS Stock Holding History

Quantbot Technologies’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,900
Closed -$47.6K – 1495
2024
Q1 		$47.6K Buy
+19,900
New +$49K ﹤0.01% 1334
2023
Q2 		– Sell
-11,400
Closed -$78K – 1613
2023
Q1 		$78K Buy
+11,400
New +$88.5K 0.01% 1154
2021
Q4 		– Sell
-548
Closed -$8K – 1553
2021
Q3 		$8K Buy
548
+131
+31% +$1.92K ﹤0.01% 1368
2021
Q2 		$5K Buy
+417
New +$5.91K ﹤0.01% 1359
2020
Q4 		– Sell
-1,700
Closed -$31K – 1342
2020
Q3 		$31K Buy
+1,700
New +$31.6K ﹤0.01% 938
2020
Q1 		– Sell
-143
Closed -$2K – 972
2019
Q4 		$2K Sell
143
-153
-52% -$2.82K ﹤0.01% 1151
2019
Q3 		$5K Buy
+296
New +$5.91K ﹤0.01% 1204
2018
Q3 		– Sell
-5,162
Closed -$72K – 1288
2018
Q2 		$72K Buy
5,162
+2,953
+134% +$42.3K ﹤0.01% 933
2018
Q1 		$24K Buy
+2,209
New +$24.2K ﹤0.01% 1053
2017
Q1 		– Sell
-521
Closed -$14K – 1163
2016
Q4 		$14K Buy
+521
New +$14.6K ﹤0.01% 954
2016
Q1 		– Sell
-5,387
Closed -$123K – 1166
2015
Q4 		$123K Buy
+5,387
New +$139K 0.02% 596

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quantbot Technologies's CHRS Position: Q2 2024 in Review

Quantbot Technologies sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 19,900 shares — an estimated $47.6K sold.

Quantbot Technologies first reported a position in CHRS in Q4 2015 and held it in 11 quarters. The position peaked at $123K in Q4 2015. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • Quantbot Technologies reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • Quantbot Technologies sold 19,900 Coherus Oncology shares in Q2 2024, an estimated $47.6K.
  • Quantbot Technologies first reported a position in Coherus Oncology in Q4 2015 and held it in 11 quarters.
  • Quantbot Technologies's Coherus Oncology position peaked at $123K in Q4 2015.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Quantbot Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.